Obicetrapib

N/A

Report date: 2024/02/21 13:42:42
NME

Base Information

Drug NameObicetrapib
Drug Alias Nameobicetrapibum奥西曲匹obicetrapibAMG-899DEZ-001 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCholesteryl ester transfer protein inhibitors
TargetsCholesteryl ester transfer protein
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHyperlipoproteinemiasHypercholesterolemia +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[24] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMitsubishi Tanabe Pharma
China Registration ClassN/A

Develop Information

Active CompaniesDezima Pharma BvMenarini GroupNewAmsterdam Pharma BV +[4] 
Inactive CompaniesMitsubishi Tanabe Pharma CorpXention Ltd
Active IndicationsHeterozygous familial hypercholesterolemiaHyperlipoproteinemiasHypercholesterolemia +[14] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A